Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 93

1.

Long-term efficacy of adalimumab after drug withdrawal and retreatment in patients with active non-radiographically evident axial spondyloarthritis who experience a flare.

Haibel H, Heldmann F, Braun J, Listing J, Kupper H, Sieper J.

Arthritis Rheum. 2013 Aug;65(8):2211-3. doi: 10.1002/art.38014. No abstract available.

2.

Adalimumab significantly reduces inflammation and serum DKK-1 level but increases fatty deposition in lumbar spine in active ankylosing spondylitis.

Hu Z, Xu M, Li Q, Lin Z, Liao Z, Cao S, Wei Q, Zhang YL, Li T, Jin O, Huang J, Pan Y, Wu Y, Deng X, Gu J.

Int J Rheum Dis. 2012 Aug;15(4):358-65. doi: 10.1111/j.1756-185X.2012.01734.x. Erratum in: Int J Rheum Dis. 2012 Dec;15(6):564.

PMID:
22898215
3.

Adalimumab for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis - a five-year update.

Poddubnyy D, Rudwaleit M.

Expert Opin Biol Ther. 2013 Nov;13(11):1599-611. doi: 10.1517/14712598.2013.839653. Review.

PMID:
24074224
4.

Efficacy and safety of adalimumab in Chinese adults with active ankylosing spondylitis: results of a randomised, controlled trial.

Huang F, Gu J, Zhu P, Bao C, Xu J, Xu H, Wu H, Wang G, Shi Q, Andhivarothai N, Anderson J, Pangan AL.

Ann Rheum Dis. 2014 Mar;73(3):587-94. doi: 10.1136/annrheumdis-2012-202533.

PMID:
23475983
5.

A multicenter, open-label, efficacy, pharmacokinetic, and safety study of adalimumab in Japanese patients with ankylosing spondylitis.

Kobayashi S, Harigai M, Mozaffarian N, Pangan AL, Sharma S, Brown LS, Miyasaka N.

Mod Rheumatol. 2012 Aug;22(4):589-97. doi: 10.1007/s10165-011-0557-x.

6.

Clinical characteristics of Japanese patients with axial spondyloarthritis, and short-term efficacy of adalimumab.

Otsuka A, Morita M, Yamada H.

J Orthop Sci. 2015 Nov;20(6):1070-7. doi: 10.1007/s00776-015-0755-z.

7.

Early response to adalimumab predicts long-term remission through 5 years of treatment in patients with ankylosing spondylitis.

Sieper J, van der Heijde D, Dougados M, Brown LS, Lavie F, Pangan AL.

Ann Rheum Dis. 2012 May;71(5):700-6. doi: 10.1136/annrheumdis-2011-200358.

8.

Double-blind, placebo-controlled randomized trial with adalimumab for treatment of juvenile onset ankylosing spondylitis (JoAS): significant short term improvement.

Horneff G, Fitter S, Foeldvari I, Minden K, Kuemmerle-Deschner J, Tzaribacev N, Thon A, Borte M, Ganser G, Trauzeddel R, Huppertz HI.

Arthritis Res Ther. 2012 Oct 24;14(5):R230. doi: 10.1186/ar4072.

9.

Adalimumab is effective and well tolerated in treating patients with ankylosing spondylitis who have advanced spinal fusion.

Rudwaleit M, Olivieri I, Boki KA, Griep EN, Järvinen P, Wong RL, Kron M, Kary S, Kupper H.

Rheumatology (Oxford). 2009 May;48(5):551-7. doi: 10.1093/rheumatology/kep022.

PMID:
19254918
10.

Efficacy of TNFα blockers in patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis: a meta-analysis.

Callhoff J, Sieper J, Weiß A, Zink A, Listing J.

Ann Rheum Dis. 2015 Jun;74(6):1241-8. doi: 10.1136/annrheumdis-2014-205322. Review.

PMID:
24718959
11.

Adalimumab: in non-radiographic axial spondyloarthritis.

Burness CB, Deeks ED.

Drugs. 2012 Dec 24;72(18):2385-95. doi: 10.2165/11470250-000000000-00000.

PMID:
23231024
12.

Effects of adalimumab therapy on musculoskeletal manifestations and health-related quality of life in patients with active psoriatic arthritis.

Tsuji S, Higashiyama M, Inaoka M, Tomita T, Yokomi A, Satoh A, Hirano A, Hayashi M, Tsuji M, Kunugiza Y, Hamada M, Yoshikawa H.

Mod Rheumatol. 2013 May;23(3):529-37. doi: 10.1007/s10165-012-0700-3.

PMID:
22752535
13.

[Anti-TNFα therapy in ankylosing spondylitis: symptom control and structural damage modification].

Andreu JL, Otón T, Sanz J.

Reumatol Clin. 2011 Jan-Feb;7(1):51-5. doi: 10.1016/j.reuma.2009.03.007. Review. Spanish.

14.

Adalimumab, etanercept and infliximab for the treatment of ankylosing spondylitis: a systematic review and economic evaluation.

McLeod C, Bagust A, Boland A, Dagenais P, Dickson R, Dundar Y, Hill RA, Jones A, Mujica Mota R, Walley T.

Health Technol Assess. 2007 Aug;11(28):1-158, iii-iv. Review.

15.

Health-related quality of life outcomes in patients with active ankylosing spondylitis treated with adalimumab: results from a randomized controlled study.

Davis JC Jr, Revicki D, van der Heijde DM, Rentz AM, Wong RL, Kupper H, Luo MP.

Arthritis Rheum. 2007 Aug 15;57(6):1050-7.

17.

Efficacy and safety of adalimumab for the treatment of peripheral arthritis in spondyloarthritis patients without ankylosing spondylitis or psoriatic arthritis.

Paramarta JE, De Rycke L, Heijda TF, Ambarus CA, Vos K, Dinant HJ, Tak PP, Baeten DL.

Ann Rheum Dis. 2013 Nov;72(11):1793-9. doi: 10.1136/annrheumdis-2012-202245.

PMID:
23139265
18.

Adalimumab significantly reduces both spinal and sacroiliac joint inflammation in patients with ankylosing spondylitis: a multicenter, randomized, double-blind, placebo-controlled study.

Lambert RG, Salonen D, Rahman P, Inman RD, Wong RL, Einstein SG, Thomson GT, Beaulieu A, Choquette D, Maksymowych WP.

Arthritis Rheum. 2007 Dec;56(12):4005-14.

19.

Treatment of non-radiographic axial spondyloarthritis: it is only the beginning.

van der Horst-Bruinsma IE.

Ann Rheum Dis. 2013 Jun;72(6):789-90. doi: 10.1136/annrheumdis-2012-202908. No abstract available.

PMID:
23667168
20.

Adalimumab effectively reduces the rate of anterior uveitis flares in patients with active ankylosing spondylitis: results of a prospective open-label study.

Rudwaleit M, Rødevand E, Holck P, Vanhoof J, Kron M, Kary S, Kupper H.

Ann Rheum Dis. 2009 May;68(5):696-701. doi: 10.1136/ard.2008.092585.

Supplemental Content

Support Center